Biopharmaceutical CMO and CRO Market Report 2026

The biopharmaceutical cmo and cro market size has grown strongly in recent years. It will grow from $35.6 billion in 2025 to $38.01 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing complexity of biologic drug development, rising R&D costs for biopharmaceutical companies, expansion of clinical trial activities, growth in biosimilar development, availability of specialized contract service providers.

The biopharmaceutical cmo and cro market size is expected to see strong growth in the next few years. It will grow to $48.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for advanced biologics manufacturing, rising investments in cell and gene therapies, expansion of global clinical trial pipelines, growing focus on speed-to-market strategies, increasing adoption of digitalized CRO services. Major trends in the forecast period include increasing outsourcing of biologic drug manufacturing, rising demand for end-to-end contract research services, growing focus on flexible manufacturing capacity, expansion of cell and gene therapy development support, enhanced emphasis on regulatory compliance services.

The rising investment in research and development is expected to propel the growth of the biopharmaceutical CMO and CRO market going forward. Increased R&D spending is driven by factors such as the demand for innovation, competitive pressures, evolving market needs, and government incentives. These investments enable CMOs and CROs to develop advanced manufacturing methods and research processes, enhancing operational efficiency and capabilities. This focus on innovation helps attract and retain clients by providing cutting-edge solutions while ensuring regulatory compliance. For instance, in September 2025, according to Eurostat, the Luxembourg-based statistical agency, the EU spent approximately $456 billion USD on research and development (R&D) in 2023 (€389 billion), with R&D expenditure relative to GDP rising to 2.26%, up from 2.22% the previous year. Therefore, rising research and development investment is driving growth in the biopharmaceutical CMO and CRO market.

Major companies in the biopharmaceutical CMO and CRO market are forming strategic partnerships to enhance services, improve efficiencies, and accelerate drug development for biopharmaceutical firms. Strategic partnerships allow companies to leverage each other’s strengths and resources to achieve mutual benefits. For instance, in June 2024, Abzena plc., a UK-based biopharmaceutical company, partnered with Argonaut Manufacturing Services Inc., a US-based contract manufacturing organization (CMO), to integrate drug development and manufacturing solutions for clients. This partnership aims to provide accelerated, end-to-end drug development and manufacturing services, enhancing efficiency, reducing costs, and streamlining biopharmaceutical production.

In June 2024, Great Point Partners, a US-based investment firm, acquired Lyocontract GmbH for an undisclosed amount. This acquisition allows Great Point Partners to expand Lyocontract’s contract manufacturing capabilities, including aseptic liquid filling, freeze-drying, and injectable medicine packaging. Lyocontract GmbH is a Germany-based drug product contract development and manufacturing organization (CDMO).

Major companies operating in the biopharmaceutical cmo and cro market are Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Eurofins Scientific SE, Lonza Group AG, Syneos Health Inc., Catalent Inc., Charles River Laboratories International Inc., Parexel International (MA) Corporation, Samsung Biologics Co. Ltd., CELLTRION INC., Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies UK Limited, Almac Group, Pharmaron Beijing Co. Ltd., Worldwide Clinical Trials, KBI Biopharma, Inotiv Inc., Caidya, Rentschler Biopharma SE, Celerion Inc., TFS HEALTHCARE LIMITED.

North America was the largest region in the biopharmaceutical CMO and CRO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo and cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biopharmaceutical cmo and cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the biopharmaceutical CMO and CRO market by increasing costs of imported bioreactors, single-use systems, analytical instruments, laboratory reagents, and manufacturing equipment. Biopharmaceutical hubs in North America and Europe are most affected due to reliance on cross-border equipment sourcing, while Asia-Pacific faces cost pressures on export-oriented contract manufacturing operations. These tariffs are increasing service costs and project timelines. However, they are also encouraging regional capacity expansion, localized manufacturing investments, and long-term strengthening of domestic biopharmaceutical service ecosystems.

The biopharmaceutical cmo and cro market research report is one of a series of new reports that provides biopharmaceutical cmo and cro market statistics, including biopharmaceutical cmo and cro industry global market size, regional shares, competitors with a biopharmaceutical cmo and cro market share, detailed biopharmaceutical cmo and cro market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical cmo and cro industry. This biopharmaceutical cmo and cro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biopharmaceutical contract manufacturing organizations (CMOs) and contract research organizations (CROs) are specialized companies that provide outsourced services to biopharmaceutical firms. CMOs primarily handle the manufacturing and production of drugs, while CROs focus on research and development, including clinical trials, regulatory support, and preclinical studies. Both types of organizations help biopharmaceutical companies reduce operational costs, accelerate timelines, and improve efficiency in drug development.

The main product types in the biopharmaceutical CMO and CRO market are biologics and biosimilars. Biologics are complex therapeutic medicines derived from living organisms, used to treat conditions such as cancer, autoimmune disorders, and infectious diseases. These organizations provide a range of services, including contract manufacturing and contract research, utilizing various biological sources, such as mammalian and non-mammalian systems, to develop and produce these therapies.

The biopharmaceutical CMO and CRO market includes revenues earned by entities by providing services such as formulation development, quality control and assurance, clinical trial management, data management, and analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.